Gluten Intolerance Treatment Market Size & Share, by Drug Type (Antihistamines, Epinephrine); Gluten-Related Disorders (Celiac Disease, Dermatitis Herpetiformis, Gluten Ataxia, Wheat Allergy, Non-Celiac Gluten Sensitivity); Pharmacy Distribution Channel (Hospital, Retail, Specialty, Online) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5081
  • Published Date: Jun 28, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Gluten Intolerance Treatment Market size is anticipated to surpass USD 3 Billion by the end of 2035, growing at a CAGR of 14% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry of gluten intolerance treatment was around USD 650 Million. The market growth is backed by the growing research on how to reverse gluten intolerance. This is resulting in the rise in clinical trials and the development of workable gluten intolerance treatments.

The rising incidence of gluten-related disorders (GRDs) and the rise in their global prevalence is predicted in about 5% of the population. The ingestion of the gluten proteins present in wheat, barley, and rye is considered the main cause of GRDs. GRDs refer to a group of conditions that are heterogeneous, reflecting their autoimmune, allergic, and non-autoimmune-allergic etiology. The increasing adoption of gluten intolerance treatment by people suffering from GRDs is will positively impact the growth of the market.


Gluten Intolerance Treatment Market
Get more information on this report: Request Free Sample PDF

Gluten Intolerance Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Prevalence of Autoimmune, Allergic, and Non-autoimmune-allergic GRDs – such as dermatitis herpetiformis (DH), celiac diseases, gluten ataxia (GA), wheat allergy (WA), and non-celiac gluten sensitivity (NCGS). As per some studies potentially over 41% of all people with ataxia of unknown origin may have gluten ataxia.
  • Rising Damage of Gut Flora or Dysbiosis – owing to the high usage of antibiotics or consuming food that they can’t digest. Gluten which is a protein is commonly found in wheat, barley, and other grains. Their increasing presence in a lot of processed foods and drinks, including pasta, cereal, and beer, and in things like vitamins, cosmetics, and even certain medications is responsible for the widespread gluten intolerance nowadays. In the United States, nearly 6% of the population is gluten intolerant.
  • Increasing Research & Development – an international research team from Italy and France uncovered a new molecular player in the development of gluten intolerance. The discovery that is published in The EMBO Journal, suggests potential targets for the development of therapeutic approaches for the disease.

Challenges

  • Challenge Associated with Diagnosis – the same clinical manifestations for different GRDs that have specific pathophysiological responses to the ingestion of gluten can make their differential diagnosis challenging which is considered a major factor affecting the market growth.
  • Lack of Awareness
  • Need for Customized Treatment

Gluten Intolerance Treatment Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~14%

Base Year Market Size (2022)

~ USD 650 Million

Forecast Year Market Size (2035)

~ USD 3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Gluten Intolerance Treatment Segmentation

Gluten-Related Disorders {Celiac Disease (CD), Dermatitis Herpetiformis (DH), Gluten Ataxia (GA), Wheat Allergy (WA), Non-Celiac Gluten Sensitivity (NCGS)}

The celiac disease segment in the gluten intolerance treatment market is set to hold the largest revenue share of 40% by 2035. Celiac disease is one of the most common examples of several types of gluten intolerance and people with celiac disease also use gluten intolerance treatment as they have high levels of certain antibodies in their blood, which are substances that fight gluten.

The increasing prevalence of celiac disease which is a serious autoimmune disease where the ingestion of gluten leads to damage in the small intestine is also considered to propel the segment growth. According to a prediction, celiac disease affects 1 in 100 people worldwide, but only around 30% are properly diagnosed. Moreover, as gluten sensitivity and celiac disease cause a lot of the same symptoms, the increase in the disease share is expected to provide numerous growth opportunities to the market players.

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Specialty Pharmacy, Online Pharmacy)

Gluten intolerance treatment market from the retail pharmacy segment is poised to register significant growth rate through 2035, owing to the rise in demand for over-the-counter (OTC) medications. Going forward most gluten-tolerance or allergy drugs need a prescription for an over-the-counter allergy drug which is predicted to be the major growth factor of the segment.

Our in-depth analysis of the market includes the following segments:

            Type

  • Antihistamines
  • Epinephrine

           Gluten-Related Disorders

  • Celiac Disease (CD)
  • Dermatitis Herpetiformis (DH)
  • Gluten Ataxia (GA)
  • Wheat Allergy (WA)
  • Non-Celiac Gluten Sensitivity (NCGS)

           Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy
 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Gluten Intolerance Treatment Industry - Regional Synopsis

European Market Forecast

The Europe gluten intolerance treatment market is slated to register about 34% revenue share by the end of 2035. The increasing review of the broad spectrum of gluten-related disorders, with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance will drive its treatment market in the region.

The prevalence of celiac disease, primarily in Northern European, specifically, in countries like Finland that have a relatively high rate of this condition is gradually leading the region towards improved methods of diagnosis and recognition and treatment of such conditions, bolstering the regional market expansion. Nearly 2.5% of all adults between the ages of 30 and 64 have been diagnosed with celiac disease in Finland.

APAC Market Statistics

The Asia Pacific region is projected to account for 25% of the overall gluten intolerance treatment market share by 2035. The growing concern about gluten intolerance that is on the rise among Asians, especially among the population of China and India is anticipated to boost the market demand in the region.

China and India are the most populous countries in the world and the increasing evolution of modern farming practices for wheat cultivation, with advancements in food processing, has resulted in higher gluten content in wheat which is considered a major factor that will lead to the higher incidence of gluten intolerance in the region.

Research Nester
Gluten Intolerance Treatment Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Gluten Intolerance Treatment Landscape

top-features-companies
    • Takeda Pharmaceutical Company Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • ActoBio Therapeutics, Inc.
    • Precigen, Inc.
    • Calypso Biotech BV
    • ImmunogenX, Inc.
    • Alvine Pharmaceuticals
    • Dr. Falk Pharma GmbH
    • ImmusanT, Inc.
    • Zedira GmbH
    • FunZyme BioTechnologies S.A.
    • Amyra Biotech AG

In-the-news

In The News

  • ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon Corporation announced that the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017. It is an innovative orally-delivered therapeutic candidate for the treatment of celiac disease.
  • Takeda Pharmaceutical Company Limited, Zedira GmbH and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227. TAK-227 is a Phase 2b investigational therapy for the treatment of celiac disease designed to prevent the immune response to gluten in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage to the small intestine.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5081
  • Published Date: Jun 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora are the major factors driving the growth of the gluten intolerance treatment market.

The market of gluten intolerance treatment is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Precigen, Inc., ImmunogenX, Inc., Calypso Biotech BV, Zedira GmbH, and FunZyme BioTechnologies S.A.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type. gluten-related disorders, distribution channel, and region.

The celiac disease segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Challenges in diagnoses are estimated to be the growth hindering factors for the market expansion.

The market in the Europe region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Gluten Intolerance Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying